SILVER SPRING, Md., March 20, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has contracted with Austrianova Singapore (Austrianova), a subsidiary of SG Austria in which Nuvilex is a partial owner, to perform the cGMP (Current Good Manufacturing Practices)-compliant encapsulation of live cells to be used for Nuvilex’s clinical trials in patients with advanced, inoperable pancreatic cancer and associated conditions and other types of cancer. A manufacturing agreement that covers all aspects of the production of the encapsulated live cells has been signed by Nuvilex and Austrianova.
Help employers find you! Check out all the jobs and post your resume.
